June 2025 in “Medical Science Journal for Advance Research” This study found that patients with Alopecia Areata had significantly higher levels of the chemokines MIG and IP-10 compared to healthy controls, suggesting these molecules may serve as potential biomarkers for diagnosing and monitoring the condition.
106 citations
,
January 2013 in “Clinical and Developmental Immunology” This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.
April 2024 in “International journal of molecular sciences” This source reports that for treating keloids and hypertrophic scars, combination pharmacotherapy targeting multiple sites is generally more effective than using a single drug, though outcomes of individual therapies vary and the development of satisfying treatments is ongoing.
105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” This review discusses the use of recombinant cytokines as therapeutic agents in clinical settings and describes the range of cutaneous complications associated with their use, including both minor and severe skin reactions.
64 citations
,
July 2016 in “Journal of Immunology” In this study, blocking the CXCR3 receptor in mice prevented the development of alopecia areata by inhibiting the accumulation of specific T cells in the skin, suggesting a potential therapeutic approach for humans.